, June 1
/PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced it will present a corporate update at the 9th Annual Needham Healthcare Conference to be held at the New York Palace Hotel, 455 Madison Avenue in New York City
. Michelle Burris
, senior vice president and chief operating officer, and John Bencich
, vice president and chief financial officer, are scheduled to present on Thursday, June 10
at 2:40 pm ET
in the Henry conference room (5th floor). The presentation will be available via audio webcast at: http://www.wsw.com/webcast/needham38/trbn/
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the Company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules as well as simultaneously neutralizing soluble ligands. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.
SOURCE Trubion Pharmaceuticals, Inc.